studied 211 patients with stage I/II DLBCL who received R‐CHOP‐like regimen with or without RT and showed that 33 (16%) had double expression of MYC and BCL2, and the double expression of MYC and BCL2 did not correlate with poor PFS (p = 0.552) and OS (p = 0.439) in their patients.35 The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.